Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
DAWN Analyst Ratings
Strong Buy
9 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
DAWN Stock 12 Month Forecast
Average Price Target
$23.25
▲(243.43% Upside)
| Highest Price Target$34.00 | Average Price Target$23.25 | Lowest Price Target$16.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$25
Buy
269.28%
Upside
Reiterated
09/26/25
Analysts Are Bullish on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Crinetics Pharmaceuticals (CRNX)Valuation and Risks. Now that we have a full year of OJEMDA commercial sales data, combined with updated 2025 revenue guidance of $140–150M, we have revised our long-term OJEMDA revenue curve to reflect a more measured adoption trajectory consistent with real-world utilization Our price target of $25 is based on an equally weighted composite of: (a) $22.62/share, as a 25x multiple of taxed and diluted FY34 GAAP EPS of $2.51 discounted back to and (b) an NPV of $27.5/ share (discount rate 12%, terminal growth rate of 2.0%).
Piper Sandler
$25
Buy
269.28%
Upside
Initiated
08/18/25
J.P. Morgan
―
Buy
―
Reiterated
08/11/25
Needham
$27→$16
Buy
136.34%
Upside
Reiterated
08/06/25
Bank of America Securities
$20→$17
Buy
151.11%
Upside
Reiterated
08/06/25
JonesTrading
$26
Buy
284.05%
Upside
Reiterated
08/06/25
Goldman Sachs
$18
Buy
165.88%
Upside
Reiterated
07/15/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$25
Buy
269.28%
Upside
Reiterated
09/26/25
Analysts Are Bullish on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Crinetics Pharmaceuticals (CRNX)Valuation and Risks. Now that we have a full year of OJEMDA commercial sales data, combined with updated 2025 revenue guidance of $140–150M, we have revised our long-term OJEMDA revenue curve to reflect a more measured adoption trajectory consistent with real-world utilization Our price target of $25 is based on an equally weighted composite of: (a) $22.62/share, as a 25x multiple of taxed and diluted FY34 GAAP EPS of $2.51 discounted back to and (b) an NPV of $27.5/ share (discount rate 12%, terminal growth rate of 2.0%).
Piper Sandler
$25
Buy
269.28%
Upside
Initiated
08/18/25
J.P. Morgan
―
Buy
―
Reiterated
08/11/25
Needham
$27→$16
Buy
136.34%
Upside
Reiterated
08/06/25
Bank of America Securities
$20→$17
Buy
151.11%
Upside
Reiterated
08/06/25
JonesTrading
$26
Buy
284.05%
Upside
Reiterated
08/06/25
Goldman Sachs
$18
Buy
165.88%
Upside
Reiterated
07/15/25
Best Analysts Covering Day One Biopharmaceuticals
1 Month
xxx
Success Rate
9/15 ratings generated profit
Average Return
+3.77%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +3.77% per trade.
3 Months
xxx
Success Rate
5/13 ratings generated profit
Average Return
+13.83%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 38.46% of your transactions generating a profit, with an average return of +13.83% per trade.
1 Year
Success Rate
6/15 ratings generated profit
Average Return
-15.23%
reiterated a buy rating 2 months ago
Copying Alec Stranahan's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -15.23% per trade.
2 Years
xxx
Success Rate
5/15 ratings generated profit
Average Return
-16.21%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -16.21% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
DAWN Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
14
14
13
11
10
Buy
0
0
0
1
1
Hold
4
2
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
16
14
13
12
Each month's total comprises the sum of three months' worth of ratings.
DAWN Financial Forecast
DAWN Stock Forecast FAQ
What is DAWN’s average 12-month price target, according to analysts?
Based on analyst ratings, Day One Biopharmaceuticals’s 12-month average price target is 23.25.
What is DAWN’s upside potential, based on the analysts’ average price target?
Day One Biopharmaceuticals has 243.43% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is DAWN a Buy, Sell or Hold?
Day One Biopharmaceuticals has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.
What is Day One Biopharmaceuticals’s price target?
The average price target for Day One Biopharmaceuticals is 23.25. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $34.00 ,the lowest forecast is $16.00. The average price target represents 243.43% Increase from the current price of $6.77.
The highest analyst price target is $34.00 ,the lowest forecast is $16.00. The average price target represents 243.43% Increase from the current price of $6.77.
What do analysts say about Day One Biopharmaceuticals?
Day One Biopharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of DAWN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.